Saturday, February 12, 2022 1:24:05 AM
On March 3, 2017, a Kasten Merger Sub merged with and into the private company Thru Pharma, LLC, d/b/a DAKOTA Life Sciences (“DAKOTA”), with the Merger Sub as the surviving corporation. The LLC Member Interests of DAKOTA were converted into the Merger Consideration comprising 42,000,000 shares of Kasten common stock.
NOW there doesn’t seem to be a single good thing that came off this. The company had the CE tagged for a while and didn’t file a single financial report after the merger. Arguably no value was added.
If Caren moves to have these 42 million shares canceled it might get granted. That’s huge for common shareholders and would make a reverse merger possible.
I can’t believe no one is discussing this here!
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM